Zentalis Pharmaceuticals
$34.509876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$34.50
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
+$0.41 (+1.20%) Today
$0.00 (0.00%) As of 6:00 PM EDT after-hours
Why Robinhood?
You can buy or sell ZNTL and other stocks, options, ETFs, and crypto commission-free!
About ZNTL
Zentalis Pharmaceuticals, Inc. Common Stock, also called Zentalis Pharmaceuticals, is a clinical-stage biopharmaceutical company focused on discovering and developing clinically differentiated, novel small molecule therapeutics targeting fundamental biological pathways of cancer. Read More It develops a broad pipeline of product candidates with an initial focus on validated oncology targets with the potential to address large patient populations. Its lead product candidate, ZN-c5, is an oral selective estrogen receptor degrader (SERD) for the treatment of estrogen receptor positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) advanced or metastatic breast cancer. The company was founded by Kevin D. Bunker on December 23, 2014 and is headquartered in New York, NY.
Employees
62
Headquarters
New York, New York
Founded
2014
Market Cap
1.38B
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
246.22K
High Today
$34.67
Low Today
$33.61
Open Price
$33.95
Volume
50.87K
52 Week High
$59.32
52 Week Low
$22.00